Literature DB >> 10491408

Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes.

Y B Kim1, S E Nikoulina, T P Ciaraldi, R R Henry, B B Kahn.   

Abstract

To determine whether the serine/threonine kinase Akt (also known as protein kinase B) is activated in vivo by insulin administration in humans, and whether impaired activation of Akt could play a role in insulin resistance, we measured the activity and phosphorylation of Akt isoforms in skeletal muscle from 3 groups of subjects: lean, obese nondiabetic, and obese type 2 diabetic. Vastus lateralis biopsies were taken in the basal (overnight fast) and insulin-stimulated (euglycemic clamp) states. Insulin-stimulated glucose disposal was reduced 31% in obese subjects and 63% in diabetic subjects, compared with lean subjects. Glycogen synthase (GS) activity in the basal state was reduced 28% in obese subjects and 49% in diabetic subjects, compared with lean subjects. Insulin-stimulated GS activity was reduced 30% in diabetic subjects. Insulin treatment activated the insulin receptor substrate-1-associated (IRS-1-associated) phosphoinositide 3-kinase (PI 3-kinase) 6.1-fold in lean, 3.7-fold in obese, and 2.4-fold in diabetic subjects. Insulin also stimulated IRS-2-associated PI 3-kinase activity 2.2-fold in lean subjects, but only 1.4-fold in diabetic subjects. Basal activity of Akt1/Akt2 (Akt1/2) and Akt3 was similar in all groups. Insulin increased Akt1/2 activity 1.7- to 2. 0-fold, and tended to activate Akt3, in all groups. Insulin-stimulated phosphorylation of Akt1/2 was normal in obese and diabetic subjects. In lean subjects only, insulin-stimulated Akt1/2 activity correlated with glucose disposal rate. Thus, insulin activation of Akt isoforms is normal in muscle of obese nondiabetic and obese diabetic subjects, despite decreases of approximately 50% and 39% in IRS-1- and IRS-2-associated PI 3-kinase activity, respectively, in obese diabetic subjects. It is therefore unlikely that Akt plays a major role in the resistance to insulin action on glucose disposal or GS activation that is observed in muscle of obese type 2 diabetic subjects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491408      PMCID: PMC408433          DOI: 10.1172/JCI6928

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  63 in total

1.  Report of the expert committee on the diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

2.  Localization of rate-limiting defect for glucose disposal in skeletal muscle of insulin-resistant type I diabetic patients.

Authors:  H Yki-Järvinen; K Sahlin; J M Ren; V A Koivisto
Journal:  Diabetes       Date:  1990-02       Impact factor: 9.461

3.  Covalent phosphorylation in the regulation glycogen synthase activity.

Authors:  R J Roach; J Larner
Journal:  Mol Cell Biochem       Date:  1977-05-03       Impact factor: 3.396

4.  Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake.

Authors:  A W Thorburn; B Gumbiner; F Bulacan; P Wallace; R R Henry
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

Review 5.  The role of protein phosphorylation in the hormonal control of enzyme activity.

Authors:  P Cohen
Journal:  Eur J Biochem       Date:  1985-09-16

6.  Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  P Damsbo; A Vaag; O Hother-Nielsen; H Beck-Nielsen
Journal:  Diabetologia       Date:  1991-04       Impact factor: 10.122

7.  Pathogenesis of NIDDM. A balanced overview.

Authors:  R A DeFronzo; R C Bonadonna; E Ferrannini
Journal:  Diabetes Care       Date:  1992-03       Impact factor: 19.112

8.  Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus.

Authors:  A W Thorburn; B Gumbiner; F Bulacan; G Brechtel; R R Henry
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

9.  Impaired activation of skeletal muscle glycogen synthase in non-insulin-dependent diabetes mellitus is unrelated to the degree of obesity.

Authors:  A B Johnson; M Argyraki; J C Thow; I R Jones; D Broughton; M Miller; R Taylor
Journal:  Metabolism       Date:  1991-03       Impact factor: 8.694

10.  A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region.

Authors:  A Bellacosa; J R Testa; S P Staal; P N Tsichlis
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

View more
  120 in total

1.  Closing in on the cause of insulin resistance and type 2 diabetes.

Authors:  M J Brady; A R Saltiel
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 2.  Signaling pathways in insulin action: molecular targets of insulin resistance.

Authors:  J E Pessin; A R Saltiel
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

Review 3.  Obesity and insulin resistance.

Authors:  B B Kahn; J S Flier
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

4.  Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver.

Authors:  Kazuaki Miyake; Wataru Ogawa; Michihiro Matsumoto; Takehiro Nakamura; Hiroshi Sakaue; Masato Kasuga
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

5.  IRS1 degradation and increased serine phosphorylation cannot predict the degree of metabolic insulin resistance induced by oxidative stress.

Authors:  R Potashnik; A Bloch-Damti; N Bashan; A Rudich
Journal:  Diabetologia       Date:  2003-05-15       Impact factor: 10.122

Review 6.  Insulin signaling defects in type 2 diabetes.

Authors:  Ying Leng; Håkan K R Karlsson; Juleen R Zierath
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

7.  Knockdown of NYGGF4 increases glucose transport in C2C12 mice skeletal myocytes by activation IRS-1/PI3K/AKT insulin pathway.

Authors:  Xue-Qi Zeng; Chun-Mei Zhang; Mei-Ling Tong; Xia Chi; Xi-Ling Li; Chen-Bo Ji; Rong Zhang; Xi-Rong Guo
Journal:  J Bioenerg Biomembr       Date:  2012-04-18       Impact factor: 2.945

8.  Postreceptoral adipocyte insulin resistance induced by nelfinavir is caused by insensitivity of PKB/Akt to phosphatidylinositol-3,4,5-trisphosphate.

Authors:  Ilana Kachko; Adva Maissel; Livnat Mazor; Ronit Ben-Romano; Robert T Watson; June C Hou; Jeffrey E Pessin; Nava Bashan; Assaf Rudich
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

9.  Human triglyceride-rich lipoproteins impair glucose metabolism and insulin signalling in L6 skeletal muscle cells independently of non-esterified fatty acid levels.

Authors:  M T Pedrini; M Kranebitter; A Niederwanger; S Kaser; J Engl; P Debbage; L A Huber; J R Patsch
Journal:  Diabetologia       Date:  2005-03-04       Impact factor: 10.122

10.  Akt2 influences glycogen synthase activity in human skeletal muscle through regulation of NH₂-terminal (sites 2 + 2a) phosphorylation.

Authors:  Martin Friedrichsen; Jesper B Birk; Erik A Richter; Rasmus Ribel-Madsen; Christian Pehmøller; Bo Falck Hansen; Henning Beck-Nielsen; Michael F Hirshman; Laurie J Goodyear; Allan Vaag; Pernille Poulsen; Jørgen F P Wojtaszewski
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-15       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.